The U.S. House of Representatives passed U.S. Senator Marco Rubio’s (R-FL) Pensacola and Perdido Bays Estuary of National Significance Act (S. 50) to direct the Environmental Protection Agency to formally enroll the Pensacola and Perdido Bays Estuary Program (PPBEP)...
News
Latest News
Rubio Statement on Nomination to Lead State Department
U.S. Senator Marco Rubio (R-FL) released a statement on his nomination by President-elect Donald J. Trump to serve as the United States Secretary of State. “Leading the U.S. Department of State is a tremendous responsibility, and I am honored by the trust President...
ICYMI: Rubio Joins The World Over With Raymond Arroyo
U.S. Senator Marco Rubio (R-FL) joined The World Over with Raymond Arroyo to discuss President-elect Donald Trump’s historic victory, the Democrats’ response to the election, foreign policy challenges facing our nation, and more. See below for highlights and watch the...
ICYMI: Rubio Joins America Reports
U.S. Senator Marco Rubio (R-FL) joined America Reports to discuss President-elect Donald Trump’s historic victory, Democrats’ proclamation of “resistance,” and the failure of identity politics. See below for highlights and watch the full interview on YouTube and...
Inauguration Ticket Information
Senator Rubio's office is pleased to be issuing a limited number of tickets to President-elect Donald Trump's inauguration ceremony, which will occur on January 20, 2025 at the West Front of the U.S. Capitol. Floridians interested in receiving tickets should fill out...
ICYMI: Rubio Joins Hannity
U.S. Senator Marco Rubio (R-FL) joined Hannity to discuss President-elect Donald Trump’s historic victory. See below for highlights and watch the full interview on YouTube and Rumble. On the ongoing realignment among American voters: “The Republican Party now reflects...
Rubio Introduces Bill to Combat Illegal Sale of Fentanyl, Other Drugs Online
Washington, D.C. — U.S. Senators Marco Rubio (R-FL) and Amy Klobuchar (D-MN) introduced the Domain Reform for Unlawful Drug Sellers (DRUGS) Act (S. 3399) to provide the U.S. Food and Drug Administration (FDA) the authority to suspend websites run by criminal networks that traffic fentanyl, counterfeit medications, and other illegal drugs. The bill, based on a successful pilot program from the FDA and the National Telecommunications and Information Administration, would require registries and registrars to lock those domain names, identified by trusted notifiers, as facilitating the sale of illicit drugs and then suspend them. The bill provides for an appeals process to allow legitimate online pharmacies to demonstrate they are operating legally and safely. A one-pager of the legislation is available here.
“Florida ranks second in the nation for overdose deaths, and far too many families across the country find themselves torn apart by drug addiction,” Rubio said. “We need to crack down on bad actors, including those from China, that target our youth and families with the online sales of counterfeit and illicit drugs like fentanyl. Without legislative action, this highly addictive drug will continue to fuel the growing opioid crisis in America. I encourage my colleagues to support this bill and give our communities the protection they need.”
“The opioid epidemic is hurting communities across our nation—none have been immune to its devastating effects,” Klobuchar said. “This bipartisan legislation will help eliminate unlawful digital pharmacies and other marketplaces illegally selling opioids or substandard drugs online, a major step as we work to address this public health emergency. Moving forward, I’ll keep pushing for policies to stop illegal sale of opioids and assist families impacted by this epidemic.”
The DRUGS Act has been endorsed by the Alliance for Safe Online Pharmacies, the National Association of Boards of Pharmacy, the National Consumers League, RESOLVE: The National Infertility Association, the International Federation of Pharmaceutical Wholesalers, the Coalition for Online Accountability, the Partnership for Safe Medicines, and the Pharmaceutical Security Institute.